Contract with Customer, Expiration Period

No definition available.

Name:	surf_ContractWithCustomerExpirationPeriod
Namespace Prefix:	surf_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Contract with Customer, Liability, Additional Payments to be Received

+ References

No definition available.

+ Details

Name:	surf_ContractWithCustomerLiabilityAdditionalPaymentsToBeReceived
Namespace Prefix:	surf_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contract With Customer, Transaction Price

+ References

No definition available.

+ Details

Name:	surf_ContractWithCustomerTransactionPrice
Namespace Prefix:	surf_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Percentage of share holding by related party.

+ References

No definition available.

+ Details

Name:	surf_PercentageOfShareHoldingByRelatedParty
Namespace Prefix:	surf_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential milestones payment.

+ References

No definition available.

+ Details

Name:	surf_PotentialMilestonesPayment
Namespace Prefix:	surf_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585

+ Details

Name:	us-gaap_PaymentsForLossesAndLossAdjustmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123385629&loc=SL5834089-161433

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name:	us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=surf_NovartisInstitutesForBiomedicalResearchIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=surf_NovartisCollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedContractCostAxis=surf_MilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedContractCostAxis=surf_SalesMilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=surf_GSKAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=surf_TransitionServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=surf_LicenseSupplyServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedContractCostAxis=surf_ClinicalMilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedContractCostAxis=surf_RegulatoryMilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2016	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue - related party		$ 0	$ 38,592,000	$ 15,360,000
Revenue performance obligation		0
License-related revenue		2,687,000	87,570,000	0
Novartis Institutes for Biomedical Research, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for reimbursement of manufacturing costs incurred		0	0
Novartis Collaboration
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue - related party		0	38,592,000	15,360,000
Novartis Collaboration \| Novartis Institutes for Biomedical Research, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for reimbursement of manufacturing costs incurred		0	0	0
Novartis Collaboration \| Novartis Institutes for Biomedical Research, Inc. \| Milestone Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestones payment		325,000,000
Novartis Collaboration \| Novartis Institutes for Biomedical Research, Inc. \| Sales Milestone Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestones payment		200,000,000
Novartis Collaboration \| Novartis Institutes for Biomedical Research, Inc. \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of share holding	5.00%
GSK Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue performance obligation		$ 0
Expiration period of GSK Agreement (in years)		10 years
Transaction price		$ 90,264,000
GSK Agreement \| License
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License-related revenue		2,687,000	87,570,000	$ 0
GSK Agreement \| Transition Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License-related revenue		733,000	0
GSK Agreement \| Supply Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License-related revenue		1,954,000	2,570,000
GSK Agreement \| Transferred at Point in Time \| License
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License-related revenue			$ 85,000,000
GSK Agreement \| Transferred over Time \| License
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional payments to be received		4,314,000
GSK Agreement \| Transferred over Time \| Transition Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional payments to be received		950,000
GSK Agreement \| Clinical Milestone Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestones payment		90,000,000
GSK Agreement \| Regulatory Milestone Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestones payment		155,000,000
GSK Agreement \| Sales Milestone Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestones payment		$ 485,000,000